Crosstalk of Long Non-coding RNAs and EMT: Searching the Missing Pieces of an Incomplete Puzzle for Lung Cancer Therapy

Author(s): Milad Ashrafizadeh, Md Shahinozzaman, Sima Orouei, Vahideh Zarrin, Kiavash Hushmandi, Farid Hashemi, Anuj Kumar, Saeed Samarghandian, Masoud Najafi*, Ali Zarrabi*

Journal Name: Current Cancer Drug Targets

Volume 21 , Issue 8 , 2021


  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Lung cancer has the first place among cancer-related deaths worldwide and demands novel strategies in the treatment of this life-threatening disorder. The aim of this review is to explore the regulation of epithelial-to-mesenchymal transition (EMT) by long non-coding RNAs (lncRNAs) in lung cancer.

Introduction: LncRNAs can be considered as potential factors for targeting in cancer therapy, since they regulate a bunch of biological processes, e.g. cell proliferation, differentiation and apoptosis. The abnormal expression of lncRNAs occurs in different cancer cells. On the other hand, epithelial-to-mesenchymal transition (EMT) is a critical mechanism participating in migration and metastasis of cancer cells.

Methods: Different databases, including Google Scholar, Pubmed and Science direct, were searched for collecting articles using keywords such as “LncRNA”, “EMT”, and “Lung cancer”.

Results: There are tumor-suppressing lncRNAs that can suppress EMT and metastasis of lung cancer cells. Expression of such lncRNAs undergoes down-regulation in lung cancer progression and restoring their expression is of importance in suppressing lung cancer migration. There are tumor- promoting lncRNAs triggering EMT in lung cancer and enhancing their migration.

Conclusion: LncRNAs are potential regulators of EMT in lung cancer, and targeting them, both pharmacologically and genetically, can be of importance in controlling the migration of lung cancer cells.

Keywords: Lung cancer, long non-coding RNA, epithelial-to-mesenchymal transition, metastasis, cancer therapy, microRNA, cadherin.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 8
Year: 2021
Published on: 02 February, 2021
Page: [640 - 665]
Pages: 26
DOI: 10.2174/1568009621666210203110305
Price: $65

Article Metrics

PDF: 207